Meet our volunteers: Dr Katerina Tavoulari
Katerina joined the Retina UK team at the start of 2023 after hearing about the charity through her involvement in a research project at the University of Bath, where she works as an academic.
Search results
Katerina joined the Retina UK team at the start of 2023 after hearing about the charity through her involvement in a research project at the University of Bath, where she works as an academic.
Dan found out he had retinitis pigmentosa in February 2022, but he feels it has been “on cards for years”. He said he had “an inkling something was up but never did anything about it: a typical guy I guess!”
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.
Whether you are looking for practical information or emotional support, online, by phone or face-to-face, we’re here to help.
Funding from Retina UK has allowed to team to explore the viability of gene therapy as a treatment for RP and related conditions, and build a pipeline of clinical trials.
The following projects were being funded by Retina UK and have recently come to an end.
Inside this edition, register now for our AI webinar on 7 December with Dr Nikolas Pontikos.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Our monthly e-Newsletter featuring the latest updates from Retina UK.